Paracoccidioidomycosis is a complex fungal infection that plagues Latin America, caused by the thermodimorphic fungi of the genus Paracoccidioides. Our company stands at the forefront of rare disease research, specializing in conditions like paracoccidioidomycosis. With a dedicated focus on serving the needs of researchers and scientists in this niche domain, we offer comprehensive one-stop services that streamline the research process.
Overview of Paracoccidioidomycosis
Paracoccidioidomycosis is a systemic fungal infection caused by the dimorphic fungus Paracoccidioides brasiliensis and Paracoccidioides lutzii. This infectious disease primarily emerges in countries such as Brazil, Argentina, Venezuela, and Colombia, impacting individuals across these regions. The incidence of paracoccidioidomycosis showcases significant variability depending on the geographical location within Latin America. In established endemic areas of southeastern and southern Brazil, the infection rate ranges from 1 to 4 cases per 100,000 inhabitants annually.
Fig.1 Geographic distribution of paracoccidioidomycosis. (Peçanha, P. M., et al., 2022)
Pathogenesis of Paracoccidioidomycosis
Paracoccidioidomycosis initiates with the inhalation of fungal spores, usually originating from the environment, initiating a primary lung infection. Paracoccidioides spores transform into yeast cells in the lung tissue, triggering an immune response. In some instances, the fungus can disseminate through the bloodstream to other organs, such as the skin, lymph nodes, mucous membranes, and adrenal glands. The immune response typically results in granuloma formation, which can lead to tissue damage and scarring.
Fig.2 Natural history of paracoccidioidomycosis with a focus on pathogenesis. (Peçanha-Pietrobom, P. M., et al., 2023)
Vaccine and Therapeutic Development for Paracoccidioidomycosis
| Types |
Names |
Mechanism of Action |
Targets |
Research Phase |
| Vaccine |
P10+DODAB |
Reduce the influx of pulmonary neutrophils and the fungal load in comparison |
P10 |
Preclinical research |
| P10 Peptide |
Reduce the fungal burden in the lungs, liver and spleen |
P10 |
Preclinical research |
| rPb27 Protein |
Reduce levels of collagen and the chemokine receptor CCR7 in the lungs |
rPb27 |
Preclinical research |
| Small Molecule Drug |
Itraconazole |
Inhibit cell growth and promote cell death of fungi |
CYP51A1 |
Approved |
| Cotrimoxazole |
DHPS inhibitor |
DHPS |
Approved |
| Monoclonal Antibody |
mAb-anti-Ly6G |
Reduce pro-inflammatory cells, fungal load, and pro-inflammatory cytokines in mice |
Neutrophils |
Preclinical research |
| mAbF1.4 |
Reduce the pulmonary fungal burden in mice |
Glycoconjugate |
Preclinical research |
| Cell Therapy |
Mesenchymal Stem Cell Transplantation |
Attenuate the inflammatory response and fibrosis |
/ |
Preclinical research |
Our Services
Our company has advanced infectious disease models, and vaccine and therapeutic development platforms that can meet the needs of any research stage. From access to cutting-edge laboratory facilities to a vast network of experts and resources, we facilitate every stage of the research journey.
Featured Services for Paracoccidioidomycosis
- Macrophage infection by Paracoccidioides brasiliensis
- Mouse model of Paracoccidioides brasiliensis infection
- Galleria mellonella model of Paracoccidioides lutzii infection
- Others
Our dedication to pushing the boundaries of understanding and addressing the challenges of rare diseases guarantees that researchers receive the necessary support and resources to achieve groundbreaking findings in paracoccidioidomycosis and beyond. If you are interested in our services, please feel free to contact us for more details and quotation information for related services.
References
- Peçanha, Paulo Mendes et al. "Paracoccidioidomycosis: What We Know and What Is New in Epidemiology, Diagnosis, and Treatment." Journal of fungi (Basel, Switzerland) 8.10 (2022): 1098.
- Peçanha-Pietrobom, Paula Massaroni et al. "Diagnosis and Treatment of Pulmonary Coccidioidomycosis and Paracoccidioidomycosis." Journal of fungi (Basel, Switzerland) 9.2 (2023): 218.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
